NICE supports Braftovi in the treatment of BRAF-positive metastatic colorectal cancer

The National Institute for Health and Care Excellence (NICE) supports the joint treatment of BRAF-positive metastatic colorectal cancer by encorafenib.
NICE initially rejected Braftovi in September after finding high cost-benefit estimates.
, however, NICE has now decided to recommend the drug in association with cetuximab for adult patients with BRAF V600E mutation-positive metastatic colorectal cancer (mCRC) who have previously received systemic treatment.
NICE's decision was based on the results of the BEACON CRC III. phase clinical trial, which showed that Braftovi combined cetuximab significantly improved the mesoth overall survival rate in patients with BRAF V600E mutant mCRC and reduced the risk of death by 39%.
treatment also produced improved objective remission rates compared to the control group. laura McMullin, managing director of
Fabre UK and Ireland, said: "We are delighted that NICE recognises the value of Braftovi's joint cetuximab for this high-demand group of people.
We would like to thank NHS England for their efforts and we hope that as many people as possible will benefit from this innovative treatment."
。